CELGENE Celgene Launches Psoriatic Arthritis Educational Patient-Focused Program
February 25, 2015
Celgene, the maker of OTEZLA® (apremilast)-the first and only oral U.S. FDA-approved therapy for the treatment of adult patients with active psoriatic arthritis (PsA) - announced the launch of the "pSAY YES!" program, a patient-focused initiative to help people with psoriatic arthritis address areas of their lives that are often impacted because of the chronic nature of the disease and help them pSAY YES to a different approach to disease management, including treatment.
As part of the "pSAY YES!" program, Celgene has enlisted the help of PsA patients from across the country, as well as chronic illness life coach Rosalind Joffe and leading rheumatologist Dr. Joseph Markenson, to develop tips specifically for patients living with and managing their disease. Tips are focused on areas most commonly impacted by psoriatic arthritis including work, hobbies and relationships. To help guide patients, the program also provides suggestions for speaking with their healthcare provider and working with them to map out the right treatment plan.
Research shows that psoriatic arthritis can have a considerable physical and emotional toll on patients. In fact, 63 percent of patients report that the condition causes them to lead less active lives, and close to half found that the disease impacts their ability to work. Additionally, patients have also reported that the disease strongly impacts their relationships, work, hobbies, and treatment regimen.
For tips and resources tailored to helping patients navigate these areas of their lives, and to learn more about the program visit pSAYYES.com.
About Psoriatic ArthritisPsoriatic arthritis is a painful, chronic inflammatory disease characterized by pain, stiffness, swelling and tenderness of the joints, inflammation of specific ligaments and tendons, and decrease in physical functioning. It is estimated that nearly 38 million people worldwide have psoriatic arthritis. Psoriatic arthritis can impact day-to-day activities and has been reported to increase work disability. Common signs and symptoms of psoriatic arthritis include pain, stiffness, and swelling in joints. To learn more about psoriatic arthritis, go to discoverpsa.com.
APPROVED USEOtezla® (apremilast) is a prescription medicine approved for the treatment of adult patients with active psoriatic arthritis
IMPORTANT SAFETY INFORMATION You must not take Otezla® (apremilast) if you are allergic to apremilast or to any of the ingredients in Otezla. Otezla is associated with an increase in adverse reactions of depression. In clinical studies, some patients reported depression, suicidal thoughts, and suicidal behavior while taking Otezla. Some patients stopped taking Otezla due to depression. Before starting Otezla, tell your doctor if you have had feelings of depression, suicidal thoughts, or suicidal behavior. Be sure to tell your doctor if any of these symptoms or other mood changes develop or worsen during treatment with Otezla. Some patients taking Otezla lost body weight. Your doctor should monitor your weight regularly. If unexplained or significant weight loss occurs, your doctor will decide if you should continue taking Otezla. Some medicines may make Otezla less effective, and should not be taken with Otezla. Tell your doctor about all the medicines you take, including prescription and nonprescription medicines. Side effects of Otezla were diarrhea, headache, and nausea.These are not all the possible side effects with Otezla. Ask your doctor about other potential side effects. Tell your doctor about any side effect that bothers you or does not go away.
Tell your doctor if you are pregnant, planning to become pregnant, or planning to breastfeed. Otezla has not been studied in pregnant women or in women who are breastfeeding.You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.
Please click here for Full Prescribing Information|
distributed by
|
